Seenu Hariprasad to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Seenu Hariprasad has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.992
-
Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar; 46(3):302-5.
Score: 0.348
-
Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol. 2011 Nov; 26(6):372-9.
Score: 0.276
-
Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System. Ophthalmic Surg Lasers Imaging Retina. 2018 12 01; 49(12):913-917.
Score: 0.113
-
The evolving paradigm for the treatment of diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2013 Jul-Aug; 44(4):324-8.
Score: 0.078
-
Current concepts in managing wet AMD suboptimally responsive to anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2013 May-Jun; 44(3):225-6.
Score: 0.077
-
Use of intravitreous bevacizumab to treat macular edema in West Nile virus chorioretinitis. Arch Ophthalmol. 2012 Mar; 130(3):396-8.
Score: 0.071
-
Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. Ocul Immunol Inflamm. 2011 Feb; 19(1):32-8.
Score: 0.016
-
Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol. 2008 Apr; 92(4):584.
Score: 0.013